Inflammation Industry Stocks($CHRS, $AMGN, $PFE...): A Remarkable 8.36% Gain in the Last Month
The inflammation industry primarily comprises biotech and pharmaceutical companies that focus on the treatment of cancer, inflammation, and other diseases related to cell proliferation. Noteworthy players in this domain include Karyopharm Therapeutics Inc., Allakos Inc., and Zymeworks.
Tickers in Industry - $CHRS, $AMGN, $PFE, $JNJ, $ATXS, $RETA, $ANAB, $ZYME
Swing Trader: Medium Volatility Stocks for Active Trading (TA&FA)
Notable Companies
The most prominent companies in this sector are Johnson & Johnson (NYSE:JNJ), Pfizer (NYSE:PFE), and Amgen (NASDAQ:AMGN).
Market Capitalization Insights
The average market capitalization across the inflammation theme stands at $67.2B. The range for individual tickers spans from a modest $13.8M to a staggering $448.3B. Johnson & Johnson (JNJ) holds the crown for the highest valuation at $448.3B, while FWP is on the other end of the spectrum, valued at $13.8M.
Recent Market Cap Movements:
- 5/2/23 1:42 PM: Johnson & Johnson (JNJ, $163.6) witnessed an $85.2B dip in market cap.
- 4/6/23 7:15 AM: Johnson & Johnson (JNJ, $165.61) enjoyed a market cap surge of $22.2B.
- 3/17/23 7:07 AM: Johnson & Johnson (JNJ, $154.03) saw its market cap rise by $86.7B.
Price Fluctuations and Noteworthy News
The average weekly price growth for stocks in the inflammation theme was -1.83%. On a monthly scale, the growth was 0.67%, and quarterly, it was 4.06%. ANAB led the pack with a price growth of 4.1%, while ALLK faced the steepest decline at -24.26%.
Significant Price Movements:
- 8/15/23 2:53 PM: Coherus BioSciences (CHRS, $4.53) took a hit, declining by -9.76%.
- 7/22/23 1:50 PM: Johnson & Johnson (JNJ, $170.19) emerged as a top performer, soaring by +6.46%.
- 7/7/23 7:30 AM: Coherus BioSciences (CHRS, $4.64) made headlines with a +10.74% jump, signaling a potential uptrend reversal.
Volume Dynamics The inflammation theme experienced an average weekly volume growth of 90.97%. Monthly volume growth averaged at 251.01%, and quarterly growth was an impressive 398.6%.
Volume Highlights:
- 8/9/23 4:12 AM: AnaptysBio stock's volume skyrocketed, marking a record-breaking daily growth of 591% of the 65-Day Volume Moving Average.
- 8/4/23 7:38 AM: Zymeworks stock followed suit with a daily growth of 272% of the 65-Day Volume Moving Average.
- 8/1/23 8:27 AM: Reata Pharmaceuticals stock also made waves with a daily growth of 224% of the 65-Day Volume Moving Average.
Fundamental Analysis Ratings
The industry's average fundamental analysis ratings, where 1 represents the best and 100 the worst, are as follows: [Data not provided]
In conclusion, the inflammation industry stocks have showcased significant growth and activity over the past month. With an average gain of 8.36%, it's evident that this sector is one to watch closely in the financial landscape.
CHRS - On August 15, 2023, CHRS marked its third consecutive day of decline, registering a -4.49% downward trend. Historically, such a three-day fall is perceived negatively in the market. Analyzing past patterns, out of 332 instances where CHRS faced a three-day drop, it continued to decline in 277 cases in the subsequent month. This suggests an 83% likelihood of the stock's continued descent. Investors are advised to monitor CHRS closely.
PFE - On August 09, 2023, PFE witnessed a positive shift in its Moving Average Convergence Divergence (MACD) Histogram. Historical data reveals that when PFE's MACD has turned positive in the past, the stock experienced an upward trajectory in 24 out of 41 instances in the succeeding month. This indicates a 59% probability of the stock maintaining its upward momentum. Investors should keep a close watch on PFE's performance.
JNJ - On July 31, 2023, JNJ's 10-day RSI Oscillator transitioned from the overbought zone, hinting at a possible shift from an ascending to a descending trend. Investors might contemplate selling the stock or considering put options. An analysis by Tickeron's A.I.dvisor, based on 37 similar past events, revealed that in 22 instances, the stock's value decreased in the subsequent days. This suggests a 59% likelihood of a downward movement for JNJ in the near future. Investors are advised to proceed with caution.
